Fiasp is a drug owned by Novo Nordisk Inc. It is protected by 1 US drug patent filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 25, 2030. Details of Fiasp's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8324157 | Preparation comprising insulin, nicotinamide and an amino acid |
Jun, 2030
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Fiasp's patents.
Latest Legal Activities on Fiasp's Patents
Given below is the list of recent legal activities going on the following patents of Fiasp.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 May, 2024 | US8324157 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 May, 2020 | US8324157 |
| Recordation of Patent Grant Mailed
Critical | 04 Dec, 2012 | US8324157 |
| Patent Issue Date Used in PTA Calculation
Critical | 04 Dec, 2012 | US8324157 |
| Email Notification
Critical | 15 Nov, 2012 | US8324157 |
| Issue Notification Mailed
Critical | 14 Nov, 2012 | US8324157 |
| Email Notification
Critical | 14 Nov, 2012 | US8324157 |
| Mail Acknowledgement of Priority Papers-Pub | 07 Nov, 2012 | US8324157 |
| Dispatch to FDC | 06 Nov, 2012 | US8324157 |
| Acknowledgement of Priority Papers-Pub | 05 Nov, 2012 | US8324157 |
FDA has granted several exclusivities to Fiasp. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Fiasp, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Fiasp.
Exclusivity Information
Fiasp holds 3 exclusivities. All of its exclusivities have expired in 2022. Details of Fiasp's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 29, 2020 |
| M(M-247) | Oct 21, 2022 |
| New Patient Population(NPP) | Dec 19, 2022 |
US patents provide insights into the exclusivity only within the United States, but
Fiasp is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Fiasp's family patents as well as insights into
ongoing legal events
on those patents.
Fiasp's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Fiasp's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 25, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Fiasp Generics:
There are no approved generic versions for Fiasp as of now.
Alternative Brands for Fiasp
There are several other brand drugs using the same active ingredient (Insulin Aspart) as Fiasp. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Novo |
| |||||||||
| Novo Nordisk Inc |
|
About Fiasp
Fiasp is a drug owned by Novo Nordisk Inc. Fiasp uses Insulin Aspart as an active ingredient. Fiasp was launched by Novo in 2017.
Approval Date:
Fiasp was approved by FDA for market use on 29 September, 2017.
Active Ingredient:
Fiasp uses Insulin Aspart as the active ingredient. Check out other Drugs and Companies using Insulin Aspart ingredient
Dosage:
Fiasp is available in solution form for intravenous, subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1000 UNITS/10ML (100 UNITS/ML) | SOLUTION | Prescription | INTRAVENOUS, SUBCUTANEOUS |